Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done

Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S95-101. doi: 10.1093/cid/civ608.


Despite the availability of effective diagnostics and curative treatment regimens for tuberculosis, millions of people die each year of this disease. The steady global increase in the number of tuberculosis cases caused by multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis are of major concern, especially in light of the thin tuberculosis drug pipeline. New tuberculosis drugs are undergoing clinical evaluation, and renewed hope comes from fresh approaches to improve treatment outcomes using a range of adjunct host-directed cellular and repurposed drug therapies. Current efforts in developing second-generation and new rapid point-of-care diagnostic assays take advantage of recent genetic and molecular advances. Slow progress in the development of prophylactic and therapeutic vaccines requires increased funding for basic as well as translational research. Although major challenges remain, these can be overcome by cementing our resolve, raising advocacy, bolstering global funder investments, and leveraging more effective collaborations through equitable public-private partnerships.

Keywords: drug resistance; new treatment regimens; research; resource-limited settings; tuberculosis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antitubercular Agents* / pharmacology
  • Antitubercular Agents* / therapeutic use
  • Biomedical Research* / economics
  • Drug Discovery
  • Global Health
  • Health Resources
  • Humans
  • Molecular Diagnostic Techniques
  • Mycobacterium tuberculosis* / drug effects
  • Mycobacterium tuberculosis* / genetics
  • Point-of-Care Systems
  • Tuberculosis* / diagnosis
  • Tuberculosis* / drug therapy
  • Tuberculosis* / prevention & control
  • Tuberculosis* / therapy
  • Tuberculosis, Multidrug-Resistant / diagnosis


  • Antitubercular Agents